Jazz Pharmaceuticals presents Phase 2b data for zanidatamab in HER2+ biliary tract cancer, showing a median overall survival of 15.5 months, exceeding typical chemotherapy prognosis.
Jazz Pharmaceuticals shares long-term Phase 2b data for zanidatamab in HER2-positive biliary tract cancer, demonstrating a median overall survival of 15.5 months and 18.1 months for IHC 3+ tumors. This marks the first overall survival findings from the HERIZON-BTC-01 trial. The results surpass the typical six- to nine-month prognosis for patients receiving chemotherapy after first-line therapy.
June 01, 2024
3 Articles